These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 16894535)

  • 21. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.
    Chang SS; Reuter VE; Heston WD; Bander NH; Grauer LS; Gaudin PB
    Cancer Res; 1999 Jul; 59(13):3192-8. PubMed ID: 10397265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective targeting of prostate cancer by lymphocytes redirected by a PSMA × CD3 bispecific single-chain diabody.
    Fortmüller K; Alt K; Gierschner D; Wolf P; Baum V; Freudenberg N; Wetterauer U; Elsässer-Beile U; Bühler P
    Prostate; 2011 May; 71(6):588-96. PubMed ID: 20945402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibodies and prostate-specific membrane antigen.
    Chang SS
    Curr Opin Investig Drugs; 2004 Jun; 5(6):611-5. PubMed ID: 15242249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.
    Novakova Z; Belousova N; Foss CA; Havlinova B; Gresova M; Das G; Lisok A; Prada A; Barinkova M; Hubalek M; Pomper MG; Barinka C
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
    Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
    Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
    Frigerio B; Fracasso G; Luison E; Cingarlini S; Mortarino M; Coliva A; Seregni E; Bombardieri E; Zuccolotto G; Rosato A; Colombatti M; Canevari S; Figini M
    Eur J Cancer; 2013 Jun; 49(9):2223-32. PubMed ID: 23433847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers.
    Gong MC; Chang SS; Sadelain M; Bander NH; Heston WD
    Cancer Metastasis Rev; 1999; 18(4):483-90. PubMed ID: 10855791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
    Bander NH; Nanus DM; Milowsky MI; Kostakoglu L; Vallabahajosula S; Goldsmith SJ
    Semin Oncol; 2003 Oct; 30(5):667-76. PubMed ID: 14571414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
    Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
    Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
    Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
    Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
    Vallabhajosula S; Smith-Jones PM; Navarro V; Goldsmith SJ; Bander NH
    Prostate; 2004 Feb; 58(2):145-55. PubMed ID: 14716739
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.
    Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC
    Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.
    Xing Y; Xu K; Li S; Cao L; Nan Y; Li Q; Li W; Hong Z
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapies for prostate cancer against the prostate specific membrane antigen.
    Elsässer-Beile U; Bühler P; Wolf P
    Curr Drug Targets; 2009 Feb; 10(2):118-25. PubMed ID: 19199907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2010 Sep; 70(12):1286-94. PubMed ID: 20623630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
    Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, production, and characterization of a single-chain variable fragment (ScFv) derived from the prostate specific membrane antigen (PSMA) monoclonal antibody J591.
    Parker SA; Diaz IL; Anderson KA; Batt CA
    Protein Expr Purif; 2013 Jun; 89(2):136-45. PubMed ID: 23500147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA).
    Tino WT; Huber MJ; Lake TP; Greene TG; Murphy GP; Holmes EH
    Hybridoma; 2000 Jun; 19(3):249-57. PubMed ID: 10952413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.
    Frigerio B; Franssen G; Luison E; Satta A; Seregni E; Colombatti M; Fracasso G; Valdagni R; Mezzanzanica D; Boerman O; Canevari S; Figini M
    Oncotarget; 2017 Feb; 8(7):10919-10930. PubMed ID: 28051996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.